Press Releases
-
Aug 14, 2017Closes $3M private placement
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...
-
Aug 7, 2017- Procedure approved via the FDA's single-use expanded access program and was performed at a major U.S. hospital -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...
-
Aug 4, 2017- Conference Call with Live Audio Webcast on Monday, August 14th at 9:00 AM ET -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Jul 10, 2017
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Jun 27, 2017- Strategic investor provides opportunity through future rights offering for additional gross proceeds up to $14 million -
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
